Astellas | PharmaShots

Astellas and FibroGen Report EMA’s Acceptance of MAA for Roxadustat to Treat Patients with Chronic Kidney Disease

May 21, 2020May 21, 2020Tuba Khan

Shots: The MAA is supported by P-III program which includes 9000+ patients globally and data from DOLOMITES study, results of which will be [Read More...]

PharmaShots Weekly Snapshot (April 27 -May 01, 2020)

May 4, 2020May 11, 2020Tuba Khan

WuXi Biologics and Aravive Collaborate to Develop Novel High-Affinity Bispecific Antibodies for Cancer and Fibrosis Published: Apr 30, 2020 | Tags: WuXi Biologics, Aravive, [Read More...]

Astellas Signs a Three-Year Research Alliance with Harvard University Across Multiple Therapeutic Areas

April 29, 2020April 29, 2020Tuba Khan

Shots: Astellas and Harvard enter into a 3yrs. strategic research collaboration initiated by faculty at Harvard, focused on the research and development of [Read More...]

PharmaShots Weekly Snapshot (April 06 -10, 2020)

April 13, 2020April 20, 2020Tuba Khan

Amgen Signs a Partnership with Adaptive Biotechnologies to Develop for COVID-19 Published: Apr 09, 2020 | Tags: Amgen, Adaptive Biotechnologies, Develop, Abs, COVID-19 2. [Read More...]

Astellas Reports Results of Mirabegron in P-IV PLUS Study to Reduce Overactive Bladder Symptoms in Men

Astellas Reports NMPA’s Acceptance of NDA for XOSPATA (gilteritinib) to Treat R/R AML with a FLT3 Mutation in Adults

April 10, 2020April 10, 2020Shiwani Sharma

Shots: Gilteritinib is a FMS-like tyrosine kinase 3 (FLT3) and has inhibitory activity against FLT3-ITD which is a type of FLT3mut+ found in [Read More...]

PharmaShots Weekly Snapshot (March 30 – April 03, 2020)

April 6, 2020April 13, 2020Tuba Khan

1. Sorrento Initiates the Next Phase of its Collaboration with Celularity Published: Apr 02, 2020 | Tags: Sorrento, Initiates, Next Phase, Collaboration, Celularity 2. [Read More...]

PharmaShots Weekly Snapshot (March 23-27, 2020)

March 30, 2020April 6, 2020Tuba Khan

1. Mylan Delays its Merger with Upjohn Due to COVID-19 Pandemic Published: Mar 26, 2020 | Tags: Mylan, Delays, Merger, Upjohn, Due, COVID-19 Pandemic [Read More...]

Astellas Collaborates with CytomX Therapeutics to Develop Probody T-Cell Engaging Bispecific Therapies for Cancer Indications

March 24, 2020March 25, 2020Tuba Khan

Shots: CytomX to receive $80M up front, ~$1.6B as pre/ clinical & commercial milestones, along with royalties on sales and will be responsible [Read More...]

Insights+ Exclusive: The US FDA New Drug Approvals in December 2019 and January 2020

February 21, 2020February 21, 2020Shiwani Sharma

The US FDA’s Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) have approved 48 new products [Read More...]

Astellas and Seattle Genetics’ Padcev (enfortumab vedotin-ejfv) + Keytruda Receive FDA’s Breakthrough Therapy Designation as 1L Treatment for Advanced Bladder Cancer

February 20, 2020February 20, 2020Tuba Khan

Shots: The BT designation is based on P-Ib/II EV-103 study assessing Padcev + Keytruda (pembrolizumab) in patients with LA/ mUC who are unable [Read More...]